Quick Search 
Drugs of the Future
Register or sign in

  
 
  
Drugs Fut 2021, 46(1): 89
ISSN 0377-8282
Copyright 2021 Clarivate
CCC: 0377-8282
DOI: 10.1358/dof.2021.46.1.3262261
 
 
5th CHI Annual Oligonucleotide & Precision Therapeutics (OPT) Congress. Virtual - October 20-21, 2020
Croasdell, G.
 
 
Going virtual, as all large gatherings have had to do in 2020, the Cambridge Healthtech Institute (CHI)'s 5th Annual Oligonucleotide and Precision Therapeutics (OPT) congress continued to bring together leading discovery scientists and developers, along with CMC and regulatory specialists to continue the ongoing discussion and updates on research in this area. With approximately 65% and 15% of attendees from biotech or pharma, respectively, the congress aimed to provide a platform for discussion on advances in next-generation oligonucleotide therapies including dedicated sessions looking at CMC and regulatory strategies. This report will focus on the drug development presentations given at the 2-day congress.


Full Text: PDF 
 
  



© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences